Matthew Biegler
Stock Analyst at Oppenheimer
(3.27)
# 2,500
Out of 4,966 analysts
399
Total ratings
39.7%
Success rate
2.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Biegler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OKUR OnKure Therapeutics | Reiterated: Buy | $30 → $14 | $3.54 | +295.48% | 8 | Aug 14, 2026 | |
| BMEA Biomea Fusion | Reiterated: Buy | $9 | $1.94 | +365.12% | 15 | Aug 6, 2026 | |
| GILD Gilead Sciences | Rated: Hold | n/a | $149.61 | - | 16 | Jun 15, 2026 | |
| CTMX CytomX Therapeutics | Rated: Hold | n/a | $3.72 | - | 12 | Jun 15, 2026 | |
| ARVN Arvinas | Rated: Hold | n/a | $9.59 | - | 17 | Jun 15, 2026 | |
| IDYA IDEAYA Biosciences | Rated: Hold | n/a | $40.17 | - | 20 | Jun 15, 2026 | |
| ORIC ORIC Pharmaceuticals | Rated: Hold | n/a | $13.13 | - | 23 | Jun 15, 2026 | |
| RLAY Relay Therapeutics | Rated: Hold | n/a | $18.51 | - | 18 | Jun 15, 2026 | |
| OLMA Olema Pharmaceuticals | Rated: Hold | n/a | $10.83 | - | 23 | Jun 15, 2026 | |
| ALLO Allogene Therapeutics | Reiterated: Buy | $7 | $1.98 | +253.54% | 9 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $25.13 | +98.97% | 23 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $3.77 | +138.73% | 23 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $28 | $25.82 | +8.44% | 23 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $9.08 | - | 11 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $865 | $852.03 | +1.52% | 13 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 | $17.00 | +164.71% | 2 | Mar 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $22 | $8.89 | +147.47% | 4 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $3.85 | +289.61% | 22 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $2.15 | +272.09% | 13 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $2.45 | n/a | 32 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $2.55 | n/a | 5 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $160 | $24.76 | n/a | 13 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $11.09 → $4.16 | $0.46 | n/a | 12 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $13.59 | n/a | 15 | Jul 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $0.179 | n/a | 3 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1.86 | n/a | 3 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $2.77 | n/a | 6 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 → $50 | $1.25 | n/a | 15 | Feb 17, 2022 |
OnKure Therapeutics
Aug 14, 2026
Reiterated: Buy
Price Target: $30 → $14
Current: $3.54
Upside: +295.48%
Biomea Fusion
Aug 6, 2026
Reiterated: Buy
Price Target: $9
Current: $1.94
Upside: +365.12%
Gilead Sciences
Jun 15, 2026
Rated: Hold
Price Target: n/a
Current: $149.61
Upside: -
CytomX Therapeutics
Jun 15, 2026
Rated: Hold
Price Target: n/a
Current: $3.72
Upside: -
Arvinas
Jun 15, 2026
Rated: Hold
Price Target: n/a
Current: $9.59
Upside: -
IDEAYA Biosciences
Jun 15, 2026
Rated: Hold
Price Target: n/a
Current: $40.17
Upside: -
ORIC Pharmaceuticals
Jun 15, 2026
Rated: Hold
Price Target: n/a
Current: $13.13
Upside: -
Relay Therapeutics
Jun 15, 2026
Rated: Hold
Price Target: n/a
Current: $18.51
Upside: -
Olema Pharmaceuticals
Jun 15, 2026
Rated: Hold
Price Target: n/a
Current: $10.83
Upside: -
Allogene Therapeutics
May 14, 2026
Reiterated: Buy
Price Target: $7
Current: $1.98
Upside: +253.54%
May 14, 2026
Reiterated: Buy
Price Target: $50
Current: $25.13
Upside: +98.97%
May 13, 2026
Reiterated: Buy
Price Target: $9
Current: $3.77
Upside: +138.73%
May 13, 2026
Reiterated: Buy
Price Target: $28
Current: $25.82
Upside: +8.44%
May 12, 2026
Rated: Hold
Price Target: n/a
Current: $9.08
Upside: -
Apr 30, 2026
Reiterated: Buy
Price Target: $865
Current: $852.03
Upside: +1.52%
Mar 27, 2026
Reiterated: Buy
Price Target: $45
Current: $17.00
Upside: +164.71%
Mar 6, 2026
Reiterated: Buy
Price Target: $22
Current: $8.89
Upside: +147.47%
Dec 8, 2025
Reiterated: Buy
Price Target: $15
Current: $3.85
Upside: +289.61%
Nov 14, 2025
Reiterated: Buy
Price Target: $8
Current: $2.15
Upside: +272.09%
May 14, 2025
Reiterated: Hold
Price Target: n/a
Current: $2.45
Upside: n/a
May 14, 2025
Maintained: Hold
Price Target: n/a
Current: $2.55
Upside: n/a
Dec 9, 2024
Maintained: Buy
Price Target: $160
Current: $24.76
Upside: n/a
Aug 14, 2023
Maintained: Buy
Price Target: $11.09 → $4.16
Current: $0.46
Upside: n/a
Jul 31, 2023
Rated: Hold
Price Target: n/a
Current: $13.59
Upside: n/a
Mar 2, 2023
Maintained: Buy
Price Target: $18
Current: $0.179
Upside: n/a
Dec 22, 2022
Downgraded: Hold
Price Target: n/a
Current: $1.86
Upside: n/a
Dec 22, 2022
Downgraded: Hold
Price Target: n/a
Current: $2.77
Upside: n/a
Feb 17, 2022
Maintained: Buy
Price Target: $8 → $50
Current: $1.25
Upside: n/a